Showing results (1-10 of 94) with videos related to
Sort By:
Pageof 10
The Urologic Clinics of North America|September 5, 1998
Risk assessment for metastatic testis cancerJ A McCaffrey, D F Bajorin, R J MotzerOncology (Williston Park, N.Y.)|October 23, 1997
Combined-modality therapy for bladder cancerJ A McCaffrey, D F Bajorin, H I Scher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survivalJ A McCaffrey, M Mazumdar, D F Bajorin, et al.Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinomaJ A McCaffrey, S Hilton, M Mazumdar, et al.Oncology (Williston Park, N.Y.)|February 19, 2000
Paclitaxel in the treatment of advanced urothelial cancerD F BajorinEuropean Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tractD F BajorinCancer|March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.Cancer Investigation|October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancerP M Dodd, J A McCaffrey, M Mazumdar, et al.Pageof 10